SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (2591)1/17/2001 1:22:30 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Here's the original ALXN CABG trial published in Circulation:

circ.ahajournals.org

Very convincing, albeit on a small number of patients.

I assume that they will look at the same endpoints in their new much larger trial. Note that the CK-MB endpoint is only one of several.

If the new trial produces similar results, then this will clearly be an approvable drug.

Peter